Regeneron And Sanofi To Present Phase 3 LIBERTY-CUPID Study C Study Data Evaluating Dupixent; Says Dupixent Reduced Itch And Hive Activity From Baseline, 41% Of Patients Achieved Well-Controlled Disease Status
Portfolio Pulse from Benzinga Newsdesk
Regeneron and Sanofi have announced positive results from their Phase 3 LIBERTY-CUPID Study C, which evaluated Dupixent. The study showed that Dupixent significantly reduced itch and hive activity, with 41% of patients achieving well-controlled disease status.
October 24, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's Phase 3 study of Dupixent shows promising results, potentially boosting investor confidence and stock price.
The positive Phase 3 results for Dupixent are likely to increase investor confidence in Regeneron's product pipeline, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sanofi's collaboration with Regeneron on Dupixent shows positive Phase 3 results, which may positively impact its stock price.
Sanofi's involvement in the successful Phase 3 study of Dupixent with Regeneron could enhance its market position and lead to a short-term stock price increase.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70